A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-nave Patients with Higher Risk Myelodysplastic Syndrome
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)
Sponsor: Forty Seven Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT0000
U.S. Govt. ID: NCT04313881
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, both good and bad, of magrolimab in combination with azacitidine, to those of azacitidine in combination with placebo, to find out which is better for treating patients with MDS (Myelodysplastic Syndrome). Other purposes of this study include determining the quantity of magrolimab in the blood, aspects of your disease management (e.g. if you can have less frequent blood transfusions), your quality of life and the side effects magrolimab has on the body.
Joseph Jurcic, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you willing to undergo a blood transfusion if needed? Yes No
Do you have untreated Myelodysplastic Syndrome (MDS)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator